Active	Status	Sponsor type	Region	Phase	Filter
26 Active 19 Inactive 45 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Belohlavkova, Petra
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) Jan 2024 - Dec 2024: Approval for myelofibrosis Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis Feb 2024 - Feb 2024: Completion of P2b trial for JIA Feb 2024 - Feb 2024: Exclusivity expiry in US	Active, not recruiting	3	430	Europe, Canada, US, RoW	Pelabresib, Ruxolitinib, Placebo	Constellation Pharmaceuticals	Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis	08/23	12/27
Vojacek, Jan
AKITA, NCT05126303: Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery	Terminated	2	177	Europe, Canada, US, RoW	RMC-035, ROSgard, Placebo	Guard Therapeutics AB	Acute Kidney Injury	04/23	07/23
Burkert, Jan
AKITA, NCT05126303: Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery	Terminated	2	177	Europe, Canada, US, RoW	RMC-035, ROSgard, Placebo	Guard Therapeutics AB	Acute Kidney Injury	04/23	07/23
POINTER, NCT06475274: A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery	Recruiting	2	161	Europe, Canada	RMC-035, Placebo	Guard Therapeutics AB	Kidney Injury Following Open-Chest Cardiac Surgery	10/25	10/25
Widener, Nancy
ASTER, NCT05171049 / 2021-003076-14: A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE	Recruiting	3	1655	Europe, Canada, Japan, US, RoW	Abelacimab, MAA868, Apixaban, Eliquis	Anthos Therapeutics, Inc., Itreas	Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism	12/26	02/27
MAGNOLIA, NCT05171075 / 2021-003085-12: A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE	Recruiting	3	1020	Europe, Canada, US, RoW	Abelacimab, MAA868, Dalteparin, Fragmin	Anthos Therapeutics, Inc., Itreas	Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism	12/26	02/27
Myjavec, Andrej
POINTER, NCT06475274: A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery	Recruiting	2	161	Europe, Canada	RMC-035, Placebo	Guard Therapeutics AB	Kidney Injury Following Open-Chest Cardiac Surgery	10/25	10/25